Orris

Write on secondary hyperparathyroidism.

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

Write on secondary hyperparathyroidism.

Reading File
Finding Sources
Finding Sources
Searching PubMed

"secondary hyperparathyroidism"[MeSH Terms] AND chronic kidney disease

Reading File
Reading File
Reading File
Reading File

Secondary Hyperparathyroidism

Definition

Secondary hyperparathyroidism (SHPT) is a compensatory hypersecretion of parathyroid hormone (PTH) by parathyroid glands that are themselves structurally normal (or diffusely hyperplastic) but are chronically stimulated - most commonly by chronic kidney disease (CKD), and less commonly by vitamin D deficiency or intestinal malabsorption. Unlike primary hyperparathyroidism, where an autonomous adenoma drives PTH secretion causing hypercalcemia, in secondary hyperparathyroidism "the parathyroid glands are normal but are stimulated to secrete excessive PTH secondary to hypocalcemia... circulating levels of PTH are elevated and blood levels of Ca2+ are low or normal but never high" - Costanzo Physiology, 7th Ed.

Etiology

  • Chronic kidney disease (CKD) - the dominant cause, sometimes termed CKD-Mineral and Bone Disorder (CKD-MBD)
  • Vitamin D deficiency/malabsorption (e.g., malnutrition, steatorrhea, gastric bypass)
  • Chronic renal failure with phosphate retention

Pathophysiology

The mechanism is a cascade of interlocking derangements as nephron mass declines:
  1. Phosphate retention - failing kidneys cannot excrete phosphate load, causing hyperphosphatemia.
  2. Decreased active vitamin D (calcitriol) - damaged kidneys lose 1α-hydroxylase activity, reducing conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D. This lowers intestinal calcium absorption.
  3. Hypocalcemia - from reduced calcitriol-driven gut absorption and phosphate-calcium complexing, directly stimulating the calcium-sensing receptor on parathyroid cells to increase PTH release.
  4. Elevated FGF-23 - an early phosphaturic hormone from osteocytes that further suppresses renal 1α-hydroxylase, compounding calcitriol deficiency.
  5. Skeletal resistance to PTH in uremia blunts the calcemic response, perpetuating the stimulus for more PTH secretion.
  6. Over time this drives parathyroid gland hyperplasia (diffuse, later nodular/monoclonal), and if prolonged and unchecked can progress to tertiary hyperparathyroidism - autonomous PTH hypersecretion with hypercalcemia that persists even after the underlying stimulus (e.g., renal transplantation) is corrected (Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 1690; Sabiston Textbook of Surgery).

Clinical and Systemic Consequences

  • Renal osteodystrophy - the skeletal manifestation of CKD-MBD, classically producing osteitis fibrosa cystica (subperiosteal bone resorption, bone pain, fractures) due to PTH-driven osteoclastic activity, alongside osteomalacia and adynamic bone disease patterns - Tietz Textbook of Laboratory Medicine, 7th Ed.
  • Cardiovascular calcification - disturbed calcium-phosphate metabolism accelerates vascular medial calcification, valvular calcification (aortic/mitral), and coronary calcification. Chronically elevated FGF-23 correlates with left ventricular hypertrophy, atrial fibrillation, and mortality; mineral metabolism disorders are estimated to account for roughly 17% of mortality risk in hemodialysis patients - Comprehensive Clinical Nephrology, 7th Ed.
  • Calciphylaxis (calcific uremic arteriolopathy) - a severe complication of longstanding mineral dysregulation in dialysis patients.
  • Pruritus, myopathy, and soft-tissue calcification can also occur.
  • "The clinical features of secondary hyperparathyroidism are usually dominated by the inciting chronic renal failure. Control of the hyperparathyroidism allows the bony changes (renal osteodystrophy) to..." improve - Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 1702.

Laboratory Findings

  • Elevated intact PTH (rises before calcium falls - PTH is a more sensitive early marker than serum calcium)
  • Low or low-normal serum calcium (never elevated, distinguishing it from primary/tertiary disease)
  • Hyperphosphatemia (in CKD-driven cases)
  • Elevated FGF-23
  • Low or low-normal 1,25-dihydroxyvitamin D

Management

Nonoperative (first-line):
  • Dietary phosphate restriction
  • Phosphate binders (calcium-based and non-calcium-based, e.g., sevelamer)
  • Vitamin D analogs/calcitriol supplementation to suppress PTH and restore calcium absorption
  • Calcimimetics (e.g., cinacalcet) that sensitize the parathyroid calcium-sensing receptor, reducing PTH secretion without raising serum calcium
  • Correction of underlying vitamin D deficiency where malabsorption/nutritional deficiency is the cause
Surgical (parathyroidectomy): Indicated when medical therapy fails to control PTH, calcium-phosphate product, bone pain/fractures, refractory pruritus, or progression to tertiary hyperparathyroidism with hypercalcemia - particularly relevant in dialysis-dependent and post-transplant patients (Sabiston Textbook of Surgery; Mulholland and Greenfield's Surgery, 7th Ed.; Bailey and Love's Short Practice of Surgery, 28th Ed.). Options include subtotal parathyroidectomy or total parathyroidectomy with autotransplantation.

Recent Evidence Note

A 2024 systematic review/meta-analysis (PMID: 38974573, Frontiers in Endocrinology) estimated the global prevalence of secondary hyperparathyroidism in CKD patients, reinforcing that this remains a highly prevalent and clinically significant complication across CKD stages, particularly in dialysis populations. This is consistent with, and updates the epidemiological context of, the textbook material above without contradicting the established pathophysiology or management framework.
This is a shared conversation. Sign in to Orris to start your own chat.